Prevalence of vitamin d deficiency and its related risk factor in a spanish cohort of adult HIV-infected patients: Effects of antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 28, Issue 9, 2012, Pages 763-771

  Cervero, Miguel ^a   Agud, José Luis ^a   García Lacalle, Concepción ^a   Alcázar, Victoria ^a   Torres, Rafael ^a   Jusdado, Juan José ^a   Moreno Guillén, Santiago ^b  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b Infectious Diseases Service   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALKALINE PHOSPHATASE; EFAVIRENZ; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PARATHYROID HORMONE; PROTEINASE INHIBITOR;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE TRANSMISSION; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATITUDE; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; NUTRITIONAL STATUS; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SPAIN; SUNLIGHT; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE; ETHNOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED; NUTRITIONAL ASSESSMENT; PREDICTIVE VALUE; QUESTIONNAIRE; STATISTICAL MODEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; COHORT STUDIES; FEMALE; HIV SEROPOSITIVITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NUTRITION ASSESSMENT; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SPAIN; SUNLIGHT; VITAMIN D DEFICIENCY;

EID: 84865507136     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0244     Document Type: Article

References (37)

1. Holick MF: Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
2. Wang TJ, Pencina MJ, Booth SL, et al.: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
3. Zittermann A, Frisch S, Berthold HK, et al.: Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009;89:1321-1327.
4. Heaney RP: The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005;97:13-19. (Pubitemid 41546209)
5. Ross AC, Manson JE, Abrams SA, et al.: The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 2011;96:53-58.
6. Holick MF, Siris ES, Binkley N, et al.: Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-3224. (Pubitemid 41014278)
7. Ginde AA, Liu MC, and Camargo CA Jr: Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009;169:626-632.
8. Baeke F, Takiishi T, Korf H, Gysemans C, and Mathieu C: Vitamin D: Modulator of the immune system. Curr Opin Pharmacol 2010;10:482-496.
9. Welz T, Childs K, Ibrahim F, et al.: Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010;24:1923-1928.
10. Mehta S, Giovannucci E, Mugusi FM, et al.: Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 2010; 5:e8770.
11. Viard JP, Souberbielle JC, Kirk O, et al.: Vitamin D and clinical disease progression in HIV infection: Results from the EuroSIDA study. AIDS 2011;25(10):1305-1315.
12. Dao CN, Patel P, Overton ET, et al.: Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011;52:396-405.
13. Haug CJ, Aukrust P, Haug E, et al.: Severe deficiency of 1, 25-dihydroxyvitamin D3 in human immunodeficiency virus infection: Association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998;83:3832-3838. (Pubitemid 28513558)
14. Villamor E: A potential role for vitamin D on HIV infection? Nutr Rev 2006;64:226-233. (Pubitemid 43953286)
15. Fabbriciani G and De Socio GV: Efavirenz and bone health. AIDS 2009;23:1181
16. Cozzolino M, Vidal M, Arcidiacono MV, et al.: HIV-protease inhibitors impair vitamin D bioactivation to 1, 25-dihydroxyvitamin D. AIDS 2003;17:513-520. (Pubitemid 36293104)
17. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: Effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1375-1382.
18. Rodriguez M, Daniels B, Gunawardene S, and Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009; 25:9-14.
19. Wasserman P and Rubin DS: Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIVinfected men under care. AIDS Patient Care STDS 2010; 24(4):223-227.
20. Brown TT and McComsey GA: Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010;15(3): 425-429.
21. Mueller NJ, Fux CA, Ledergerber B, et al.: High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010;24:1127-1134.
22. Conesa-Botella A, Florence E, Lynen L, et al.: Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther 2010;7:40.
23. Fox J, Peters B, Prakash M, et al.: Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. AIDS Res Hum Retroviruses 2011;27(1):29-34.
24. Wohl DA, Doroara M, Orkin C, et al.: Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-näve adults receiving TMC278 compared with EFV: 48-week results from the Phase III ECHO Trial. In 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011.
25. Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, et al.: Abnormalities in the bone mineral metabolism in HIVinfected patients. Clin Rheumatol 2006;25:537-539. (Pubitemid 44137629)
26. Calatayud M, Jodar E, Sanchez R, Guadalix S, and Hawkins F: [Prevalence of deficient and insufficient vitamin D levels in a young healthy population]. Endocrinol Nutr 2009;56: 164-169.
27. Stein EM, Yin MT, McMahon DJ, et al.: Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int 2011;22(2):477-487.
28. National Center for Health Statistics CfDCaP: NHANES analytic guidelines, 2004.
29. Thacher TD, Obadofin M, O'Brien K, and Abrams S: The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets. J Clin Endocrinol Metab 2009;94:3314-3321.
30. Overton ET, Yin MT. The rapidly evolving research on Vitamin D among HIV-infected populations. Curr Infect Dis Rep 2011;13:89-93.
31. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201. (Pubitemid 38917996)
32. McComsey GA, Kitch D, Daar E, et al.: Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: A prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. In 17th Conference on Retroviruses and Opportunistic Infections HIV-1 infection, February 16-19, 2010, San Francisco, CA
33. Cooper DA, Bloch M, and Humphries A: Simplification with fixed dose tenofovir-emtricitabine or abacavir-lamivudine adults with suppressed HIV replication (The Steal Study, randomized, open-label, 96-week, non-inferiority trial). In 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
34. Fux CA, Rauch A, Simcock M, et al.: Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008;13:1077-1082.
35. Childs KE, Fishman SL, Constable C, et al.: Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 2010;26:855-859.
36. Rosenvinge MM, Gedela K, Copas AJ, et al.: Tenofovirlinked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 2010;54:496-499.
37. European AIDS Clinical Society (EACS) Guidelines Version 6.0 October 2011. Available at www.europeanaidsclinical society.org/images/stories/EACS-Pdf/ eacsguidelines-6.pdf. Accessed 15 November 2011.